The absence of institutional selling and the strong passive buying suggest underlying confidence in CHRS at current valuations. Traders should monitor for follow-on retail or active manager participation, which could amplify upward momentum. However, given that all buyers are passive, this may reflect index inclusion or rebalancing rather than fundamental conviction.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $1.65entry
- T+1 · 9mo ago 0.00%α +0.91% · $1.65
- T+5 · 8mo ago +16.97%α +18.18% · $1.93
- T+20 · 8mo ago −3.03%α +4.91% · $1.60
- T+60 · 6mo ago −0.61%α −9.93% · $1.64
How similar events traded
Executive Summary
Three major passive institutional investors, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Coherus Oncology (CHRS) during Q4 2024, collectively adding $2.9M in new holdings with no institutional selling observed. The cluster is entirely composed of mega-passive funds doubling down or adding to existing positions, suggesting growing institutional ownership amid a stable or improving market perception.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.9M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +155.3% | $2.9M | $2.1M |
| UBS | DOUBLED | +309.4% | $978.0K | $798.0K |
| Wells Fargo | ADD | +32.4% | $85.0K | $37.0K |
Key Facts
- Morgan Stanley doubled its stake, increasing holdings by 1.28M shares ($2.1M in value).
- UBS increased its position by 309.4%, adding $798K in value.
- Wells Fargo added $37K in value with a 32.4% share increase.
- No institutional selling was reported in this quarter.
- Total net buying: $2.9M across three passive institutions.
Financial Impact
Institutions accumulated $2.9M in net new positions in CHRS during Q4 2024.
Risk Factors
- All buyers are passive managers, reducing the signal strength of active conviction.
- Market cap remains low ($250M), making the stock vulnerable to volatility despite institutional inflows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CHRS-2024-Q4 |
Track record
15 reports on CHRS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers